Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its subsidiary Xeris Pharmaceuticals Inc.'s U.S. patent application covering XP-8121, one of its novel product candidates. The Notice of Allowance indica.

Business Wire • Dec 1, 2025

Xeris Biopharma Holdings, Inc. (XERS) Q3 2025 Earnings Call Transcript

Xeris Biopharma Holdings, Inc. ( XERS ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Communications John Shannon - CEO & Director Steven Pieper - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Alexandra von Riesemann - Piper Sandler & Co., Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Presentation Operator Hello, everyone, and thank you for joining us today for the Xeris Biopharma Q3 2025 Earnings Conference Call.

Seeking Alpha • Nov 6, 2025

Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter ended September 30, 2025. “We delivered another record-breaking quarter, driven by increased patient demand across all three products,” said John Shannon, Chief Executive Officer. “Total product revenue grew 4.

Business Wire • Nov 6, 2025

Xeris Biopharma (XERS) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Nov 6, 2025

Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3

Xeris Biopharma (XERS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.01. This compares to a loss of $0.06 per share a year ago.

Zacks Investment Research • Nov 6, 2025

Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Thursday, November 6, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the.

Business Wire • Oct 23, 2025

Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue?

Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Oct 20, 2025

Are You Looking for a Top Momentum Pick? Why Xeris Biopharma (XERS) is a Great Choice

Does Xeris Biopharma (XERS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Oct 20, 2025

Xeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains?

Xeris Biopharma (XERS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Investment Research • Oct 16, 2025

Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Oct 3, 2025